HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00.
Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.
A move to $29.00 would account for a 480.0% increase from the current share price.
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
About Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
